The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Outcomes of alloSCT for AML with WT1 mutation
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses outcomes of allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML) with Wilms’ tumor 1 (WT1) mutation. Despite WT1 being a poor prognostic factor, the analysis found no significant difference in outcomes between patients with WT1 mutation and those with wild-type WT1. This is considered good news for patients, as it suggests that WT1 is not a risk factor for transplantation outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI generated)
So we looked on the outcome of AML patients with WT1 mutation undergoing allogeneic transplant with either sibling transplant, unrelated transplantation or haploidentical transplant. Because with conventional therapy, without transplantation, the WT1 is a poor prognostic factor. And so this is a rare situation with about, if I remember correct, 70 patients or so. So first of all, we found out the difference between and compared to patients with wild type WT1...
So we looked on the outcome of AML patients with WT1 mutation undergoing allogeneic transplant with either sibling transplant, unrelated transplantation or haploidentical transplant. Because with conventional therapy, without transplantation, the WT1 is a poor prognostic factor. And so this is a rare situation with about, if I remember correct, 70 patients or so. So first of all, we found out the difference between and compared to patients with wild type WT1. We found a difference in age, so the patients with WT1 were younger. We found some difference in the ELN 2022 risk factor, so the patients with WT1 had a better ELN 2022 risk category. And we also found difference in association with other mutations. The mutations were by next generation sequencing, including the WT1. So there were more CEBPA and FLT3 in the patients with the WT1 mutation. As for the outcomes, there was no difference between patients with WT1 mutation compared to the patients with the wild type, neither in leukemia-free survival, overall survival, or a GvHD relapse-free survival. So in this analysis, we failed to show, and this is good news for the patients, that WT1 is a risk factor for transplantation for patients undergoing transplant for AML.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
